Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-02-10

Clinical Trial Update: 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064) [Phase 3]

View source ↗

Summary

Phase 3 extension study results for the sitagliptin and pioglitazone combination in type 2 diabetes were completed, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PIOGLITAZONE (Pioglitazone)
  • Sitagliptin (sitagliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2010-02-10